Modalis Therapeutics Corp
TSE:4883
Modalis Therapeutics Corp
Income from Continuing Operations
Modalis Therapeutics Corp
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Modalis Therapeutics Corp
TSE:4883
|
Income from Continuing Operations
-¥2.4B
|
CAGR 3-Years
-75%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
N/A
|
|
GNI Group Ltd
TSE:2160
|
Income from Continuing Operations
¥9.5B
|
CAGR 3-Years
91%
|
CAGR 5-Years
118%
|
CAGR 10-Years
N/A
|
|
PeptiDream Inc
TSE:4587
|
Income from Continuing Operations
¥3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
Takara Bio Inc
TSE:4974
|
Income from Continuing Operations
¥1.6B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
2%
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Income from Continuing Operations
¥4.8B
|
CAGR 3-Years
39%
|
CAGR 5-Years
39%
|
CAGR 10-Years
40%
|
|
S
|
StemRIM Inc
TSE:4599
|
Income from Continuing Operations
¥168.4m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Modalis Therapeutics Corp's Income from Continuing Operations?
Income from Continuing Operations
-2.4B
JPY
Based on the financial report for Dec 31, 2023, Modalis Therapeutics Corp's Income from Continuing Operations amounts to -2.4B JPY.
What is Modalis Therapeutics Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-61%
Over the last year, the Income from Continuing Operations growth was 12%. The average annual Income from Continuing Operations growth rates for Modalis Therapeutics Corp have been -75% over the past three years , -61% over the past five years .